Paper32550266
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
Dowsett M and 18 others. NPJ Breast Cancer, 2020. Cited by 49 papers, by iCite.
Cite this record
ConductScience Library. Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. Papers, record 32550266. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32550266
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 8671 | Cancer Research UK | United Kingdom | PubMed | PubMed | |
| U01 CA114722 | NCI NIH HHS | United States | U01CA114722 | PubMed | NIH RePORTER |
| U10 CA076001 | NCI NIH HHS | United States | U10CA076001 | PubMed | NIH RePORTER |
| 25351 | Cancer Research UK | United Kingdom | PubMed | PubMed | |
| U24 CA114736 | NCI NIH HHS | United States | U24CA114736 | PubMed | NIH RePORTER |
| R01 CA095614 | NCI NIH HHS | United States | R01CA095614 | PubMed | NIH RePORTER |
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28721378 | Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. | NPJ Breast Cancer | 2016 | https://conductscience.org/library/papers/28721378 | PubMed |
| 2 | 21555689 | Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21555689 | PubMed |
| 3 | 20716629 | Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. | Ann Oncol | 2011 | https://conductscience.org/library/papers/20716629 | PubMed |
| 4 | 21960707 | Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. | J Natl Cancer Inst | 2011 | https://conductscience.org/library/papers/21960707 | PubMed |
| 5 | 32550266 | Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. | NPJ Breast Cancer | 2020 | https://conductscience.org/library/papers/32550266 | PubMed |
| 6 | 32333293 | Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. | Breast Cancer Res Treat | 2020 | https://conductscience.org/library/papers/32333293 | PubMed |
| 7 | 12751376 | Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. | Eur J Cancer | 2003 | https://conductscience.org/library/papers/12751376 | PubMed |
| 8 | 1486427 | Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment. | Br J Surg | 1992 | https://conductscience.org/library/papers/1486427 | PubMed |
| 9 | 32368252 | Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic. | Ecancermedicalscience | 2020 | https://conductscience.org/library/papers/32368252 | PubMed |
| 10 | 21802721 | Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. | Lancet | 2011 | https://conductscience.org/library/papers/21802721 | PubMed |
| 11 | 18083023 | Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. | Eur J Cancer | 2008 | https://conductscience.org/library/papers/18083023 | PubMed |
| 12 | 30523750 | Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30523750 | PubMed |
| 13 | 23958221 | WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. | Trials | 2013 | https://conductscience.org/library/papers/23958221 | PubMed |
| 14 | 28045625 | Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28045625 | PubMed |
| 15 | 15767642 | Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15767642 | PubMed |
| 16 | 17228000 | Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. | J Natl Cancer Inst | 2007 | https://conductscience.org/library/papers/17228000 | PubMed |
| 17 | 22043057 | Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. | J Natl Cancer Inst Monogr | 2011 | https://conductscience.org/library/papers/22043057 | PubMed |
| 18 | 17679728 | A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17679728 | PubMed |
| 19 | 24203987 | An international Ki67 reproducibility study. | J Natl Cancer Inst | 2013 | https://conductscience.org/library/papers/24203987 | PubMed |
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42315983 | Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negative breast cancer. | Histopathology | 2026 | https://conductscience.org/library/papers/42315983 | PubMed |
| 42211537 | The Neoadjuvant Approach to Treatment of Breast Cancer: Multidisciplinary Management to Improve Outcomes. | Surg Oncol Insight | 2024 | https://conductscience.org/library/papers/42211537 | PubMed |
| 42141291 | Early, delayed, or combined contrast-enhanced mammography for detecting residual disease after neoadjuvant chemotherapy in breast cancer. | Eur Radiol | 2026 | https://conductscience.org/library/papers/42141291 | PubMed |
| 41317270 | SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025). | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41317270 | PubMed |
| 41021566 | Impact of COVID-19 on breast cancer patients and services in a UK region: Protocol for a mixed methods study. | PLoS One | 2025 | https://conductscience.org/library/papers/41021566 | PubMed |
| 40075655 | Radiogenomic Landscape of Metastatic Endocrine-Positive Breast Cancer Resistant to Aromatase Inhibitors. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40075655 | PubMed |
| 37567612 | Ki67 and breast cancer mortality in women with invasive breast cancer. | JNCI Cancer Spectr | 2023 | https://conductscience.org/library/papers/37567612 | PubMed |
| 37326826 | SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022). | Clin Transl Oncol | 2023 | https://conductscience.org/library/papers/37326826 | PubMed |
| 37232817 | COVID-19 and Breast Cancer: Analysis of Surgical Management of a Large Referral Center during the 2020-2021 Pandemic Period. | Curr Oncol | 2023 | https://conductscience.org/library/papers/37232817 | PubMed |
| 37010651 | Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study. | Breast Cancer Res Treat | 2023 | https://conductscience.org/library/papers/37010651 | PubMed |
| 36897465 | Using Oncotype DX breast recurrence scoreĀ® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. | Breast Cancer Res Treat | 2023 | https://conductscience.org/library/papers/36897465 | PubMed |
| 36733464 | Breast Cancer Management in the Era of Covid-19; Key Issues, Contemporary Strategies, and Future Implications. | Breast Cancer (Dove Med Press) | 2023 | https://conductscience.org/library/papers/36733464 | PubMed |
| 36506043 | Clinical implication of low estrogen receptor (ER-low) expression in breast cancer. | Front Endocrinol (Lausanne) | 2022 | https://conductscience.org/library/papers/36506043 | PubMed |
| 36334188 | Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study. | Breast Cancer Res Treat | 2023 | https://conductscience.org/library/papers/36334188 | PubMed |
| 36299379 | Tailored treatment strategies for cancer patients during COVID-19 pandemic. | Rep Pract Oncol Radiother | 2022 | https://conductscience.org/library/papers/36299379 | PubMed |
| 36262803 | Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors. | Contemp Clin Trials Commun | 2022 | https://conductscience.org/library/papers/36262803 | PubMed |
| 35992886 | Research trends and hotspots of breast cancer management during the COVID-19 pandemic: A bibliometric analysis. | Front Oncol | 2022 | https://conductscience.org/library/papers/35992886 | PubMed |
| 34979596 | Impact of the COVID-19 Pandemic on the Diagnosis and Surgery of Breast Cancer: A Multi-Institutional Study. | J Breast Cancer | 2021 | https://conductscience.org/library/papers/34979596 | PubMed |
| 34965950 | Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/34965950 | PubMed |
| 34779146 | TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. | Cancer Med | 2021 | https://conductscience.org/library/papers/34779146 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32550266
GET https://conductscience.org/api/papers/v1/32550266/cited_by?page=2